Drug Safety in Pregnancy and Breastfeeding: A Complete Clinical Guide
Medication use during pregnancy and breastfeeding is one of the most nuanced areas of clinical pharmacology. Virtually every drug crosses the placenta to some degree, and most drugs are transferred to breast milk. However, the clinical significance of this exposure - and whether the benefit of treatment outweighs the risk to the fetus or infant - varies enormously between drugs, doses, trimesters and individual clinical situations. This guide provides essential background for patients and healthcare providers using our pregnancy and breastfeeding safety tools.
The FDA Pregnancy Category System and Its Replacement
From the 1970s until 2015, the FDA classified drug safety in pregnancy using five letter categories - A, B, C, D and X - based on available human and animal study evidence. While widely used, this system was criticised for oversimplifying complex risk-benefit relationships and being easily misinterpreted. In 2015, the FDA replaced this system with the Pregnancy and Lactation Labeling Rule (PLLR), which requires manufacturers to provide detailed narrative information in three sections: Pregnancy (including risk summary, clinical considerations and data), Lactation (including risk summary and clinical considerations) and Females and Males of Reproductive Potential. Our Pregnancy Category Lookup covers both the legacy categories and explains the PLLR transition. Our Pregnancy Drug Safety Checker provides both legacy category data and PLLR narrative summaries where available.
Trimester-Specific Drug Risks
The risk profile of a drug in pregnancy is not uniform across gestation. The first trimester (weeks 1–12) is the period of organogenesis - when fetal organs are forming - and is therefore the highest-risk period for teratogenic (birth defect-causing) drugs. The second trimester (weeks 13–26) is generally a lower-risk period for structural defects but drugs can still affect fetal growth and development. The third trimester (weeks 27–40) carries risks related to neonatal adaptation - for example, NSAIDs in the third trimester can cause premature closure of the ductus arteriosus, and SSRIs near term can cause neonatal adaptation syndrome. Our Pregnancy Drug Safety Checker provides trimester-specific guidance for each medication.
Medications Absolutely Contraindicated in Pregnancy
Certain medications cause such severe and predictable fetal harm that they are absolutely contraindicated throughout pregnancy. Isotretinoin (for acne) causes severe birth defects affecting virtually every organ system and requires a mandatory pregnancy prevention programme in most countries. Thalidomide causes severe limb reduction defects. Methotrexate is a known teratogen causing miscarriage and fetal defects. Warfarin in the first trimester causes warfarin embryopathy; in the third trimester it risks fetal bleeding. Valproate causes neural tube defects and long-term neurodevelopmental impairment. Statins are contraindicated due to theoretical risk from cholesterol pathway inhibition during fetal development. For patients on any of these medications, our Pregnancy Drug Safety Checker flags them clearly and suggests safer alternatives.
Drug Safety During Breastfeeding
Most medications transfer into breast milk, but the amount reaching the infant is typically a small fraction of the maternal dose. The key measure used in clinical practice is the Relative Infant Dose (RID) - the infant's dose through milk as a percentage of the weight-adjusted maternal dose. An RID below 10% is generally considered acceptable for most drugs. However, drugs with low RID may still be concerning for neonates with immature hepatic and renal clearance, or in premature infants. Our Breastfeeding Drug Safety Checker provides RID data, LactMed-referenced safety ratings and practical timing advice for feeds and pumping. For medications that require dose adjustment due to the mother's renal function, pair with our Renal Dose Adjustment Calculator.
The "Pump and Dump" Approach - When It Is and Is Not Needed
Some breastfeeding mothers are advised to "pump and dump" - express and discard breast milk - after taking a medication. This approach is appropriate for drugs with short half-lives where a single dose creates a temporary exposure window, but it is not appropriate for drugs taken regularly on a chronic basis, where milk levels at the next feed will be similar regardless. The decision should be based on the drug's half-life, peak milk concentration timing and the specific clinical situation. Our Breastfeeding Drug Safety Checker provides timing-specific guidance for relevant medications.
Interactions and Pregnancy
Pregnancy significantly alters pharmacokinetics - drug metabolism, distribution and clearance change substantially across trimesters. These changes can affect the dosing requirements of medications used in pregnancy and alter the clinical significance of drug interactions. For patients on multiple medications during pregnancy, always check interactions using our Drug Interaction Checker and discuss the full medication list with your obstetrician and pharmacist.